The Influence of Glycemic Control Over Post-extraction Healing in Diabetic Patients
Jegan M1, A Saneem Ahamed2, Vijaya Lakshmi G2
1Dentistry, Priyadarshini Dental College and Hospital, Chennai, IND.
Cureus
|November 7, 2024
Summary
This study found that random blood sugar levels between 151-240 mg/dL in diabetic patients did not significantly impact post-extraction wound healing compared to levels ≤150 mg/dL. While some minor complications increased, overall healing outcomes remained similar.
Area of Science:
- Oral Surgery
- Endocrinology
- Wound Healing Research
Background:
- Diabetes mellitus, characterized by hyperglycemia, often impairs wound healing post-dental extraction.
- Complications like infection and delayed recovery are common in diabetic patients.
- The specific impact of glycemic control on healing outcomes requires further elucidation.
Purpose of the Study:
- To compare post-extraction wound healing in insulin-dependent diabetic patients with well-controlled (RBS ≤150 mg/dL) versus moderately controlled (RBS 151-240 mg/dL) blood sugar levels.
- To assess the association between glycemic control and clinical outcomes such as pain, bleeding, infection, and dry socket.
Main Methods:
- Prospective observational study of 100 insulin-dependent diabetic patients undergoing dental extractions.
- Patients divided into two groups based on random blood sugar (RBS): Group A (≤150 mg/dL) and Group B (151-240 mg/dL).
- Clinical outcomes including pain, bleeding, infection, and wound dimensions were assessed on days 1, 7, and 14 post-extraction.
Main Results:
- Higher glycemic levels (151-240 mg/dL) were associated with increased pain and bleeding but did not significantly alter overall healing outcomes.
- Group A (RBS ≤150 mg/dL) demonstrated better healing status compared to Group B.
- No significant difference in healing outcomes was observed between the two glycemic control groups.
Conclusions:
- Glycemic levels between 151-240 mg/dL do not significantly impact post-extraction wound healing in diabetic patients compared to levels ≤150 mg/dL.
- While elevated blood sugar in this range may not impede healing, managing diabetes remains crucial to prevent adverse outcomes.
- Further research is needed to define the optimal glycemic range for superior wound healing in diabetic patients.
Related Concept Videos
Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
Diabetes: Management and Pharmacotherapy
236
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
236
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
160
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
160
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Dipeptidyl Peptidase 4 Inhibitors
172
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172
Oral Hypoglycemic Agents: Glinides
141
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
141


